🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Recent Data of #Theranostics published in the The Lancet: LuPSMA therapy can improve PFS of patients with metastatic prostate cancer before trying chemotherapy or also as a booster to chemotherapy. Kudos to the trialists! doi.org/10.1016/S1470-… doi.org/10.1016/S0140-…

Happy International Day of Medical Physics! IDMP's theme for this year is "inspiring the next generation of medical physicists," and the winner of the poster contest is Dr. Lavanya Murugan from Rajiv Gandhi Government General Hospital and Madras Medical College in Chennai, India.

SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617 jnm.snmjournals.org/content/early/…

After PSMAfore and SPLASH, The ECLIPSE trial also met its primary endpoint Hopefully we will get LuPSMA therapy approved for chemotherapy-naive mCRPC patients one day. #PSMA #theranostics #prostatecancer Curium Pharma curiumpharma.com/2024/11/13/ecl…

Moving toward precision response assessment and dynamic risk startification by SPECT/CT in mCRPC receiving LuPSMA! #PSMA #Theranostics Fred Hutch Cancer Center University of Washington Louise Emmett Michael Hofman Thomas Hope jnm.snmjournals.org/content/early/…

SPECT deserves RESPECT! Louise Emmett makes the argument that it is a powerful tool for theranostics ➤ enabling early, personalised treatment response evaluation ➤ optimizes outcomes by guiding therapy adjustments. ✓practical advantages over serial PET.

A summary of my last 24h stranded in #LAX thanks to WestJet. Delayed 5 times until flight was cancelled. Rebooked to today and delayed again 3 more times. Zero compensation…not even a bottle of water.

BIG NEWS! Yesterday the FDA expanded the indication for lutetium-177 vipivotide tetraxetan (Pluvicto), allowing its use before taxane-based chemotherapy. The new approval triples Pluvicto’s eligible patient population. More here: fda.gov/drugs/resource…

First patient treated with #Pluvicto™ in pre-chemotherapy setting following FDA approval. Dr. Steven Finkelstein joins Zach Klaassen to discuss the recent approval and his team's achievement of treating the first U.S. patient under this new indication. #WatchNow on UroToday >

Computational nuclear oncology toward precision #RPTherapy: Current tools, techniques, & uncharted territories. ow.ly/7rGQ50VuMcT Arman Rahmim Babak Saboury Joyita Dutta Prof Geoff Currie AM Abhinav Jha, Ph.D. Carlos Uribe 🧬⚛️ Julia Brosch-Lenz Emilie Roncali

An ongoing first-in-human trial aims to establish the safety, dosimetry, and preliminary efficacy of ¹⁷⁷Lu-HTK03170 in patients with PSMA-positive #mCRPC. Read more: ow.ly/tA8O50VSQ03 #NuclearMedicine #RPTherapy #ProstateCancer BC Cancer Sara Harsini